VK2735 Research# VK2735's evidence base consists of phase 2 trials: VENTURE (subcutaneous): 176 adults with obesity, 13 weeks, up to 14.7% weight loss from baseline (placebo-adjusted 13.1%) VENTURE-Oral: Oral tablet formulation, 13 weeks, up to 12.2% weight loss vs 1.3% placebo Phase 3 VANQUISH program: Planned but not yet initiated at time of writing Evidence level: Low -- promising phase 2 data only, short duration, small sample sizes, no head-to-head comparisons
Multiple studies have shown that 4mm pen needles deliver medication into the subcutaneous tissue layer accurately for adults regardless of BMI, and longer needles increase intramuscular injection risk
Your choice depends on personal preference and lifestyle
Reconstituting the drug in this manner creates a liquid solution, purportedly the equivalent of the brand-name drug, which can then be injected under the skin
How frequently you need to receive B12 shots depends on the medical conditions you suffer from due to vitamin B12 deficiency
The plan is built around your response, not your wallet